– USA, NY – Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr. Enoch Kariuki, PharmD, to its Board of Directors.
Dr. Kariuki is a highly accomplished finance executive, bringing over a decade of deep expertise in life sciences investment banking, strategic advising, and business development to Zentalis.
“We are pleased to welcome Enoch to our Board of Directors, and believe his experience as a financial leader in the healthcare sector will offer invaluable perspective for our growing organization,” said Chairman and CEO, Dr. Anthony Sun. “Over the course of his career, Enoch has played a pivotal role in follow-on offerings and multibillion-dollar mergers and acquisitions, and we look forward to applying his guidance and learnings to Zentalis’ corporate financial strategy.”
About Dr. Enoch Kariuki
Dr. Kariuki most recently served as CFO at VelosBio, a clinical-stage oncology-focused biopharmaceutical company, which was acquired by Merck. At VelosBio, he led all finance-related and investor relations functions. Before VelosBio, he served as SVP, Corporate Development at Synthorx. During his tenure, he led the company’s IPO as well as business development efforts leading up to its acquisition by Sanofi. Previously, Dr. Kariuki was VP at H.I.G. Capital, where he invested in and served on the boards of multiple life sciences companies. Earlier in his career, Dr. Kariuki held various roles in investment banking at Leerink Partners and UBS Investment Bank.
“I am honored to join Zentalis’ Board and to serve as the Chair of the Audit Committee,” commented Dr. Enoch Kariuki. “I am eager to work closely with the Zentalis team to provide collaborative and meaningful contributions as they navigate bringing potentially differentiated cancer therapeutics to patients.”
He completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol Myers Squibb and was a Pharmacist at CVS Caremark. Dr. Kariuki received an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University.
About Zentalis
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor, and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
For more information: https://zentalis.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.